Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
DRD2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ASENAPINE | ? unclear | Mechanistic | DGIdb | |
| MEPHENTERMINE | ? unclear | Mechanistic | DGIdb | |
| HALOPERIDOL LACTATE | ↓ inhibits | Mechanistic | DGIdb | |
| BREXPIPRAZOLE | ↑ activates | Mechanistic | DGIdb | |
| ANALGESIC AGENT | ? unclear | Mechanistic | DGIdb | |
| AXITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| RG-1530 | ↓ inhibits | Mechanistic | DGIdb | |
| LOXAPINE SUCCINATE | ↓ inhibits | Mechanistic | DGIdb | |
| QUETIAPINE FUMARATE | ↓ inhibits | Mechanistic | DGIdb | |
| PROCHLORPERAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| APOMORPHINE | ↑ activates | Mechanistic | DGIdb | |
| PRAMIPEXOLE | ? unclear | Mechanistic | DGIdb | |
| THIETHYLPERAZINE MALEATE | ↓ inhibits | Mechanistic | DGIdb | |
| IBCASERTIB | ↓ inhibits | Mechanistic | DGIdb | |
| FAMITINIB | ↓ inhibits | Mechanistic | DGIdb | |
| SOXATALTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| SUMANIROLE | ↑ activates | Mechanistic | 9.0 nM (Ki) | DGIdb |
| DOCARPAMINE | ? unclear | Mechanistic | DGIdb | |
| PALIPERIDONE | ↓ inhibits | Mechanistic | DGIdb | |
| PRIDOPIDINE | ~ modulates | Mechanistic | DGIdb | |
| OLANZAPINE | ↓ inhibits | Mechanistic | 20.0 nM (Ki) | DGIdb |
| PEGDINETANIB | ↓ inhibits | Mechanistic | DGIdb | |
| RISPERIDONE | ↓ inhibits | Mechanistic | DGIdb | |
| PERGOLIDE MESYLATE | ↑ activates | Mechanistic | DGIdb | |
| LISURIDE | ? unclear | Mechanistic | 0.5 nM (Ki) | DGIdb |
| ZICRONAPINE | ? unclear | Mechanistic | DGIdb | |
| CLEBOPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| LAZERTINIB | ↓ inhibits | Mechanistic | DGIdb | |
| REMOXIPRIDE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CABERGOLINE | ↑ activates | Mechanistic | DGIdb | |
| JNJ-37822681 | ↓ inhibits | Mechanistic | DGIdb | |
| ERGOT ALKALOIDS | ? unclear | Mechanistic | DGIdb | |
| (-)-STEPHOLIDINE | ? unclear | Mechanistic | DGIdb | |
| SARIZOTAN HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| 5-OH-DPAT | ? unclear | Mechanistic | DGIdb | |
| LITHIUM | ? unclear | Mechanistic | DGIdb | |
| DIHYDROERGOTOXINE | ? unclear | Mechanistic | DGIdb | |
| REMOXIPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| BROMPERIDOL | ↓ inhibits | Mechanistic | DGIdb | |
| PHENTOLAMINE | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 427 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| NCGC607 | ? unclear | Mechanistic | DGIdb | |
| AFEGOSTAT | ? unclear | Mechanistic | 60.0 nM (IC50) | DGIdb |
| GENTIAN VIOLET CATION | ? unclear | Mechanistic | DGIdb | |
| VELAGLUCERASE ALFA | ? unclear | Mechanistic | DGIdb | |
| RALOXIFENE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CIRSIMARITIN | ? unclear | Mechanistic | DGIdb | |
| DOMIPHEN BROMIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1169388 | ? unclear | Mechanistic | DGIdb | |
| 2,3-DIHYDROXY-6,7-DICHLOROQUINOXALINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL579837 | ? unclear | Mechanistic | DGIdb | |
| METITEPINE | ? unclear | Mechanistic | DGIdb | |
| TALIGLUCERASE ALFA | ? unclear | Mechanistic | DGIdb | |
| APTIGANEL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL588327 | ? unclear | Mechanistic | DGIdb | |
| MIGALASTAT | ? unclear | Mechanistic | DGIdb | |
| CHLORHEXIDINE GLUCONATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL528181 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1379900 | ? unclear | Mechanistic | DGIdb | |
| L 755507 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL73711 | ? unclear | Mechanistic | DGIdb | |
| DNQX | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL408500 | ? unclear | Mechanistic | DGIdb | |
| CASTANOSPERMINE | ? unclear | Mechanistic | DGIdb | |
| SULFANITRAN | ? unclear | Mechanistic | DGIdb | |
| AMBROXOL | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL578928 | ? unclear | Mechanistic | DGIdb | |
| PHLORETIN | ? unclear | Mechanistic | DGIdb | |
| GENISTEIN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL603154 | ? unclear | Mechanistic | DGIdb | |
| AFEGOSTAT TARTRATE | ~ modulates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL529939 | ? unclear | Mechanistic | DGIdb | |
| ISOLIQUIRITIGENIN | ? unclear | Mechanistic | DGIdb | |
| TRICHOSTATIN A | ? unclear | Mechanistic | DGIdb | |
| EBSELEN | ? unclear | Mechanistic | DGIdb | |
| CHEMBL3350088 | ↓ inhibits | Mechanistic | 150.0 nM (Ki) | ChEMBL |
| CHEMBL3350093 | ↓ inhibits | Mechanistic | 550.0 nM (Ki) | ChEMBL |
| CHEMBL3350086 | ↓ inhibits | Mechanistic | 25.1 nM (Ki) | ChEMBL |
| CHEMBL3350089 | ↓ inhibits | Mechanistic | 100.0 nM (Ki) | ChEMBL |
| CHEMBL3350092 | ↓ inhibits | Mechanistic | 1.2 nM (Ki) | ChEMBL |
| CHEMBL469844 | ↓ inhibits | Mechanistic | 200.0 nM (Ki) | ChEMBL |
Showing top 40 of 156 agents ranked by evidence tier.
LRRK2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LRRK2 INHIBITOR 6 [PMID: 40353293] | ↓ inhibits | Mechanistic | DGIdb | |
| LIRADASERTIB | ↓ inhibits | Mechanistic | DGIdb | |
| ADAVOSERTIB | ? unclear | Mechanistic | DGIdb | |
| PF-562271 | ? unclear | Mechanistic | DGIdb | |
| NIK INHIBITOR 12F | ↓ inhibits | Mechanistic | DGIdb | |
| DCLK1-IN-1 | ↓ inhibits | Mechanistic | DGIdb | |
| DACTOLISIB | ? unclear | Mechanistic | DGIdb | |
| VANDETANIB | ? unclear | Mechanistic | 1995.26 nM (Ki) | DGIdb |
| LRRK2-IN-1 | ↓ inhibits | Mechanistic | DGIdb | |
| DOVITINIB | ? unclear | Mechanistic | 1500.0 nM (Kd) | DGIdb |
| BOS172722 | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2204495 | ? unclear | Mechanistic | DGIdb | |
| TOZASERTIB | ? unclear | Mechanistic | 630.96 nM (Ki) | DGIdb |
| MLI-2 | ↓ inhibits | Mechanistic | DGIdb | |
| PALBOCICLIB | ? unclear | Mechanistic | 2511.89 nM (Ki) | DGIdb |
| ENTRECTINIB | ? unclear | Mechanistic | 2511.89 nM (Ki) | DGIdb |
| HG-10-102-01 | ↓ inhibits | Mechanistic | DGIdb | |
| RG-1530 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL379975 | ? unclear | Mechanistic | DGIdb | |
| GSK2646264 | ↓ inhibits | Mechanistic | DGIdb | |
| PD166285 | ? unclear | Mechanistic | DGIdb | |
| GNE-9605 | ↓ inhibits | Mechanistic | DGIdb | |
| PELERASERTIB | ↓ inhibits | Mechanistic | DGIdb | |
| ALISERTIB | ? unclear | Mechanistic | 794.33 nM (Ki) | DGIdb |
| AST-487 | ? unclear | Mechanistic | 950.0 nM (Kd) | DGIdb |
| PF-06447475 | ↓ inhibits | Mechanistic | DGIdb | |
| URMC-099 | ↓ inhibits | Mechanistic | DGIdb | |
| PICTILISIB | ? unclear | Mechanistic | DGIdb | |
| NVP-TAE684 | ? unclear | Mechanistic | DGIdb | |
| XMD-12 | ↓ inhibits | Mechanistic | DGIdb | |
| EB-42486 | ↓ inhibits | Mechanistic | DGIdb | |
| PF-06454589 | ↓ inhibits | Mechanistic | DGIdb | |
| NIK SMI1 | ↓ inhibits | Mechanistic | DGIdb | |
| JAK3 INHIBITOR VI | ↓ inhibits | Mechanistic | DGIdb | |
| TTT-3002 | ↓ inhibits | Mechanistic | DGIdb | |
| XL01126 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 8 [PMID: 17480064] | ? unclear | Mechanistic | DGIdb | |
| ILORASERTIB | ? unclear | Mechanistic | DGIdb | |
| CENISERTIB | ? unclear | Mechanistic | 0.631 nM (Ki) | DGIdb |
| FASUDIL | ? unclear | Mechanistic | 1995.26 nM (Ki) | DGIdb |
Showing top 40 of 206 agents ranked by evidence tier.
MAOB
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SAFINAMIDE | ↓ inhibits | Mechanistic | 450.0 nM (Ki) | DGIdb |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1927670 | ? unclear | Mechanistic | DGIdb | |
| MOCLOBEMIDE | ↓ inhibits | Mechanistic | 100000.0 nM (Ki) | DGIdb |
| CHEMBL:CHEMBL1927684 | ? unclear | Mechanistic | DGIdb | |
| SELEGILINE | ↓ inhibits | Mechanistic | 970.0 nM (Ki) | DGIdb |
| BIFEMELANE | ↓ inhibits | Mechanistic | DGIdb | |
| MEBANAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| MELATONIN | ? unclear | Mechanistic | DGIdb | |
| PARGYLINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL602260 | ? unclear | Mechanistic | DGIdb | |
| ISOCARBOXAZID | ↓ inhibits | Mechanistic | DGIdb | |
| SEROTONIN | ? unclear | Mechanistic | DGIdb | |
| [18F]FLUORORASAGILINE | ? unclear | Mechanistic | DGIdb | |
| RASAGILINE | ↓ inhibits | Mechanistic | 700.0 nM (Ki) | DGIdb |
| CHEMBL:CHEMBL1642672 | ? unclear | Mechanistic | DGIdb | |
| PHENOXYPROPAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| LAZABEMIDE | ↓ inhibits | Mechanistic | 84.0 nM (Ki) | DGIdb |
| NIALAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1813518 | ? unclear | Mechanistic | DGIdb | |
| SAFINAMIDE MESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| COBALAMIN | ? unclear | Mechanistic | DGIdb | |
| PHENELZINE | ↓ inhibits | Mechanistic | DGIdb | |
| RASAGILINE TARTRATE | ↓ inhibits | Mechanistic | DGIdb | |
| RALFINAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| SELEGILINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| VITAMIN K3 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2088303 | ? unclear | Mechanistic | DGIdb | |
| TRANYLCYPROMINE | ↓ inhibits | Mechanistic | DGIdb | |
| PARGYLINE | ? unclear | Mechanistic | 1800.0 nM (Ki) | DGIdb |
| ANTIDEPRESSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| MOFEGILINE | ? unclear | Mechanistic | DGIdb | |
| INDANTADOL | ? unclear | Mechanistic | DGIdb | |
| NAPHTHOQUINONE | ? unclear | Mechanistic | DGIdb | |
| METHAMPHETAMINE | ? unclear | Mechanistic | DGIdb | |
| HALOPERIDOL DECANOATE | ? unclear | Mechanistic | DGIdb | |
| PHENELZINE SULFATE | ↓ inhibits | Mechanistic | DGIdb | |
| IPRONIAZID | ↓ inhibits | Mechanistic | 7540.0 nM (IC50) | DGIdb |
| LINEZOLID | ↓ inhibits | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL602466 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 218 agents ranked by evidence tier.
SLC6A3
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| ALTROPANE I-123 | ? unclear | Mechanistic | DGIdb | |
| BUPROPION HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| DEXMETHYLPHENIDATE | ↓ inhibits | Mechanistic | DGIdb | |
| AMPHETAMINE ADIPATE | ? unclear | Mechanistic | DGIdb | |
| DEXTROAMPHETAMINE SACCHARATE | ? unclear | Mechanistic | DGIdb | |
| LIAFENSINE | ↓ inhibits | Mechanistic | DGIdb | |
| LISDEXAMFETAMINE DIMESYLATE | ? unclear | Mechanistic | DGIdb | |
| METHAMPHETAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| SIBUTRAMINE | ? unclear | Mechanistic | DGIdb | |
| METHYLPHENIDATE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| 3,4-METHYLENEDIOXYMETHAMPHETAMINE | ? unclear | Mechanistic | DGIdb | |
| LEVODOPA | ? unclear | Mechanistic | DGIdb | |
| DEXTROAMPHETAMINE ADIPATE | ? unclear | Mechanistic | DGIdb | |
| METYROSINE | ? unclear | Mechanistic | DGIdb | |
| ANESTHETIC AGENT | ? unclear | Mechanistic | DGIdb | |
| SERTRALINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| BENZTROPINE | ? unclear | Mechanistic | 312.0 nM (IC50) | DGIdb |
| BICIFADINE | ↓ inhibits | Mechanistic | DGIdb | |
| ALTROPANE | ? unclear | Mechanistic | DGIdb | |
| DASOTRALINE | ↓ inhibits | Mechanistic | DGIdb | |
| DISULFIRAM | ? unclear | Mechanistic | DGIdb | |
| AMITIFADINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| AMPHETAMINE ASPARTATE | ? unclear | Mechanistic | DGIdb | |
| NICOTINE POLACRILEX | ? unclear | Mechanistic | DGIdb | |
| SPIROGLUMIDE | ? unclear | Mechanistic | DGIdb | |
| HINOKININ | ? unclear | Mechanistic | DGIdb | |
| DIETHYLPROPION HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| SERDEXMETHYLPHENIDATE CHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PHENTERMINE RESIN | ? unclear | Mechanistic | DGIdb | |
| PSEUDOEPHEDRINE | ? unclear | Mechanistic | DGIdb | |
| PHENMETRAZINE | ? unclear | Mechanistic | DGIdb | |
| CENTANAFADINE | ↓ inhibits | Mechanistic | DGIdb | |
| BUPRENORPHINE | ? unclear | Mechanistic | DGIdb | |
| PYROVALERONE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| SERDEXMETHYLPHENIDATE | ↓ inhibits | Mechanistic | DGIdb | |
| PHENMETRAZINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| FENCAMFAMIN | ? unclear | Mechanistic | DGIdb | |
| IOFLUPANE I-123 | ? unclear | Mechanistic | DGIdb | |
| PHENDIMETRAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| MAZINDOL | ↓ inhibits | Mechanistic | 42.6 nM (IC50) | DGIdb |
Showing top 40 of 176 agents ranked by evidence tier.
SNCA
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHEMBL:CHEMBL1521156 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL599100 | ? unclear | Mechanistic | DGIdb | |
| DOXORUBICIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| LEVOKETOCONAZOLE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL450802 | ? unclear | Mechanistic | DGIdb | |
| CALCDPWW | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL580727 | ? unclear | Mechanistic | DGIdb | |
| PRASINEZUMAB | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL505670 | ? unclear | Mechanistic | DGIdb | |
| CONGO RED FREE ACID | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL548540 | ? unclear | Mechanistic | DGIdb | |
| GARDENIN | ? unclear | Mechanistic | DGIdb | |
| 6-AZAURIDINE | ? unclear | Mechanistic | DGIdb | |
| PARAROSANILINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL534353 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2094833 | ? unclear | Mechanistic | DGIdb | |
| GENTIAN VIOLET CATION | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2094567 | ? unclear | Mechanistic | DGIdb | |
| 2-CHLOROADENOSINE-5-TRIPHOSPHATE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL442906 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1534035 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1526167 | ? unclear | Mechanistic | DGIdb | |
| PP2 | ? unclear | Mechanistic | DGIdb | |
| MYCOPHENOLATE | ? unclear | Mechanistic | DGIdb | |
| ALTENUSIN | ? unclear | Mechanistic | DGIdb | |
| GW305074X | ? unclear | Mechanistic | DGIdb | |
| INDENEBART | ? unclear | Mechanistic | DGIdb | |
| ABT702 | ? unclear | Mechanistic | DGIdb | |
| CINPANEMAB | ↓ inhibits | Mechanistic | DGIdb | |
| LICARIN A | ? unclear | Mechanistic | DGIdb | |
| LITHOCHOLIC ACID | ? unclear | Mechanistic | DGIdb | |
| CAFFEIC ACID PHENETHYL ESTER | ? unclear | Mechanistic | DGIdb | |
| CHEMBL1594514 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1411318 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1379677 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1476741 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1565212 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1331245 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1411120 | ~ modulates | Mechanistic | ChEMBL | |
| CHEMBL1459532 | ~ modulates | Mechanistic | ChEMBL |
Showing top 40 of 221 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| METYROSINE | ↓ inhibits | Mechanistic | DGIdb | |
| STREPTOZOCIN | ? unclear | Mechanistic | DGIdb | |
| SAPONIN | ? unclear | Mechanistic | DGIdb | |
| PROSAVIN | ? unclear | Mechanistic | DGIdb | |
| OPIATE | ? unclear | Mechanistic | DGIdb | |
| FLUTAMIDE | ? unclear | Mechanistic | DGIdb | |
| 3-IODOBENZYLGUANIDINE | ? unclear | Mechanistic | DGIdb | |
| PRASTERONE | ? unclear | Mechanistic | DGIdb | |
| METHYLPHENIDATE | ? unclear | Mechanistic | DGIdb | |
| RECOMBINANT INTERFERON | ? unclear | Mechanistic | DGIdb | |
| SERTRALINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| INDOMETHACIN | ? unclear | Mechanistic | DGIdb | |
| 3-IODOTYROSINE | ↓ inhibits | Mechanistic | DGIdb | |
| 3-CHLOROTYROSINE | ↓ inhibits | Mechanistic | DGIdb | |
| SAPROPTERIN | ? unclear | Mechanistic | DGIdb | |
| DOXYCYCLINE ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| TRIAMTERENE | ? unclear | Mechanistic | DGIdb | |
| ALPHA-TOCOPHEROL | ? unclear | Mechanistic | DGIdb | |
| Α-PROPYLDOPACETAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| TYROSINE | ? unclear | Mechanistic | DGIdb | |
| PHENYLALANINE | ? unclear | Mechanistic | DGIdb | |
| METHADONE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| ANTIESTROGEN | ? unclear | Mechanistic | DGIdb | |
| EPOETIN ALFA | ? unclear | Mechanistic | DGIdb | |
| CHEMBL27559 | ↓ inhibits | Mechanistic | 42000.0 nM (IC50) | ChEMBL |
| CHEMBL330274 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| R-N-PROPYLNORAPOMORPHINE | ↓ inhibits | Mechanistic | 300.0 nM (IC50) | ChEMBL |
| CHEMBL283489 | ↓ inhibits | Mechanistic | 87000.0 nM (IC50) | ChEMBL |
| IOTYROSINE | ↓ inhibits | Mechanistic | 720.0 nM (IC50) | ChEMBL |
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Parkinson's Disease: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) gene. The duration of the intervention per patient will be 104 weeks with monthly infusions....
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
The purpose of this study is to evaluate the safety and efficacy of 34 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study consists of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Dose (MAD) stud...
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
This Phase I clinical trial is designed to evaluate the safety, tolerability of a single dose of XS411 (derived dopaminergic neural progenitor cell injection) in patients with primary Parkinson's disease. This Phase II clinical trial is designed to evaluate the safety, tolerability and Efficacy of X...
This study is researching an experimental drug called ALN-SNCA (called "study drug"). The study is focused on people with early Parkinson's disease, a disorder of the nervous system that affects movement. Parkinson's disease is caused by a gradual loss of nerve cells in the brain, especially those d...
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical tri...
The main objective of this study is to evaluate the efficacy of STW5 Iberogast, over a 28-day period, for the treatment of constipation in parkinsonian patients suffering from gastrointestinal disorders.
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhib...
An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy
This trial will evaluate the effects of Lu AF28996 in adults with Parkinson's disease (PD) experiencing motor fluctuations despite optimized non-invasive symptomatic treatment. These are individuals with PD who take medications to control movement symptoms, such as slowness, stiffness, and tremor, b...
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
The purpose of this study is to select the safest and most effective number of repeat doses of allogeneic bone marrow-derived mesenchymal stem cell (MSC) infusions to slow the progression of Parkinson's disease (PD).
The goal of this clinical trial is to compare the efficacy and safety of different Intervention Intervals of subthalamic nucleus-targeted transcranial temporal interference stimulation (STN-tTIS) in patients with Parkinson disease. Previous studies suggest that STN-tTIS may improve motor symptoms in...
Agents Found By Disease-Level Search
Searched directly from “Parkinson's Disease” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 7-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
43 agents shown (approved or with trial evidence) — 42 not found by the gene-target search above.
IstradefyllineNOT in gene-target list
ND0611NOT in gene-target list
Levodopa
HER-096NOT in gene-target list
EntacaponeNOT in gene-target list
BIA 9-1067NOT in gene-target list
best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group RecommendationsNOT in gene-target list
TUS ActiveNOT in gene-target list
PARCOPANOT in gene-target list
18F-DTBZ AV-133NOT in gene-target list
Voice-activated Intelligent Personal Assistant (VIPA)NOT in gene-target list
piribedilNOT in gene-target list
pramipexole or ropiniroleNOT in gene-target list
IPX066NOT in gene-target list
dextromethorphanNOT in gene-target list
AFFITOPE® PD01ANOT in gene-target list
Exer gamingNOT in gene-target list
conventional treatment planNOT in gene-target list
O-15 WaterNOT in gene-target list
18F-Fluoro-L-dopaNOT in gene-target list
CVT-301 (Dose Level 1)NOT in gene-target list
CVT-301 (Dose Level 2)NOT in gene-target list
Sinemet®NOT in gene-target list
High dose ANAVEX2-73NOT in gene-target list
Mid dose ANAVEX2-73NOT in gene-target list
Local Anesthesia (lidocaine hydrochloride)NOT in gene-target list
GameficiationNOT in gene-target list
local field potentials and electroencephalography recordingsNOT in gene-target list
Intravenous and Oral n-acetyl cysteineNOT in gene-target list
Oral Supplements: Baicalin, Ganoderma, Omega 3 and CurcuminNOT in gene-target list
Autologous Peripheral Nerve GraftNOT in gene-target list
ND0612NOT in gene-target list
PosiphenNOT in gene-target list
EarStimNOT in gene-target list
Sodium OxybateNOT in gene-target list
LD/CD SC solutionNOT in gene-target list
voice recordingsNOT in gene-target list
Madopar® HBSNOT in gene-target list
Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)NOT in gene-target list
Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)NOT in gene-target list
Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)NOT in gene-target list
Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)NOT in gene-target list
TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)NOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.